Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders – Business…

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of scientific research across cancers and blood disorders at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress that underscores the companys commitment to delivering transformational therapies for patients. Data from more than 140 company-sponsored studies, investigator-sponsored studies and collaborations evaluating compounds across 28 cancer types and blood disorders will be featured at the two meetings.

We have made significant progress for patients with cancer and blood disorders by delivering clinically meaningful and differentiated treatment choices across modalities such as CAR T, immunotherapy and erythroid maturation, said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. Driven by our deep understanding of human biology and leading scientific research, the results being presented at ASCO and EHA will provide greater insight into the potential for improving long-term outcomes, and rationale for moving innovative interventions into earlier lines of treatment. Beyond our data, we are focused on improving care for all patients through our Health Equity Commitments, aimed at increasing diversity in clinical trials, addressing health disparities, and investing in training for racially and ethnically diverse clinical investigators.

Key data being presented by Bristol Myers Squibb at ASCO and EHA 2022 include:

Solid Tumor

Cell Therapy

Hematology

Early Assets

Summary of Presentations

Select Bristol Myers Squibb studies at the 2022 ASCO Annual Meeting include:

Abstract Title

Author

Presentation Type/#

Session Title

Session Date/ Time

Acute Myeloid Leukemia

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).

Courtney DiNardo

Poster

Abstract #7032

Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant

Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT

Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry.

Harry Erba

Poster

Abstract #7029

Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant

Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.

Stephane De Botton

Oral

Abstract #7005

Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant

Tuesday, June 7, 2022: 10:45 AM - 1:45 PM EDT

Gastrointestinal

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.

Ian Chau

Poster

Abstract

#4035

Gastrointestinal CancerGastroesophageal, Pancreatic, and Hepatobiliary

Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT

Nivolumab (NIVO) ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

Michael Overman

Poster

Abstract

#3510

Gastrointestinal CancerColorectal and Anal

Saturday, June 4, 2022: 9:00 AM - 12:00 PM EDT

Genitourinary

Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.

Cristina Suarez

Oral

Abstract

#4501

Genitourinary CancerKidney and Bladder

Friday, June 3, 2022: 3:45 PM - 6:45 PM EDT

The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214.

David Cella

Oral

Abstract

#4502

Genitourinary CancerKidney and Bladder

Friday, June 3, 2022: 3:45 PM - 6:45 PM EDT

Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.

Daniel Geynisman

Poster

Abstract

#4548

Genitourinary CancerKidney and Bladder

Saturday, June 4, 2022: 2:15 PM - 5:15 PM EDT

Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.

Lucia Carril-Ajuria

Poster

Abstract

#4538

Genitourinary CancerKidney and Bladder

Saturday, June 4, 2022: 2:15 PM - 5:15 PM EDT

Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.

Alfred Witjes

Poster

Abstract

#4585

Genitourinary CancerKidney and Bladder

Saturday, June 4, 2022: 2:15 PM - 5:15 PM EDT

Melanoma

Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.

Hussein A. Tawbi

Oral

Abstract

#9505

Melanoma/Skin Cancers

Sunday, June 5, 2022: 10:45 AM - 1:45 PM EDT

View post:

Bristol Myers Squibb Data at ASCO and EHA 2022 Highlight Progress in Transforming Treatment for Patients with Cancer and Blood Disorders - Business...